Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Pemetrexed in Primary Unknown Adenocarcinoma
NCT00191503Phase 2
Key facts
- Status
- Completed
- Start
- Jan 2005
- Countries
- 1
- Sponsor
- Eli Lilly and Company
- Modality
- Small Molecules
- Conditions
- Adenocarcinoma
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed and gemcitabine in Adenocarcinoma, sponsored by Eli Lilly and Company. Primary endpoint: Objective Response Rate. Started Jan 2005; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Pemetrexed + Gemcitabine
Combination chemotherapy with Pemetrexed and Gemcitabine
03
Who it enrols
Patients with histologically proven adenocarcinoma of unknown origin with predominant liver metastases, ECOG 0-1, and adequate organ function.
04
Endpoints
Primary
Objective Response Rate
Secondary
Overall Survival
Toxicities of Therapy
Beyond the preview
Go deeper on NCT00191503.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00191503.